Eloralintide Dosing Guide: Phase 2 Trial Doses and Weekly Protocol

There is no FDA-approved starting dose for Eloralintide. In Lilly’s completed Phase 2 obesity trial, the lowest fixed-dose study arm evaluated 1 mg once a week. Other participants received fixed 3 mg, 6 mg, or 9 mg weekly amounts or planned increases. These were clinical-trial study arms, not consumer dosing recommendations.

Sources: [1] Phase 2 study design and exact schedules. · [2] Phase 2 weight and side-effect results. DOI: 10.1016/S0140-6736(25)02155-5.

The completed study, NCT06230523, randomly assigned 263 adults with obesity or overweight to six Eloralintide study arms or placebo. Participants did not have type 2 diabetes. Treatment lasted 48 weeks.

A study arm is a group assigned to a particular treatment schedule. Participants and researchers were kept unaware of the assigned treatment during the trial. The drug was studied as an injection under the skin once a week.

Sources: [1] Phase 2 study design and exact schedules. · [2] Phase 2 weight and side-effect results. DOI: 10.1016/S0140-6736(25)02155-5.

These are the exact schedules evaluated in the completed Phase 2 trial. Titration simply means gradually changing the amount over time. The fixed arms kept the same amount throughout the study.

The 6→9 mg arm stayed at 6 mg through Week 20, then changed at Week 21. The 3→6→9 mg arm changed at Weeks 5 and 9. These were different study schedules, not a general four-week rule.

Sources: [1] Phase 2 study design and exact schedules.

Phase 2 efficacy-estimand results: average body-weight change at Week 48. “Efficacy estimand” means the analysis estimates the treatment effect assuming participants stayed on their assigned treatment. It is different from an analysis that includes treatment stopping or changes.

The numbers below are rounded study averages. A negative number means weight loss. They describe what happened in the clinical trial and do not predict what will happen for an individual person.

Sources: [2] Phase 2 weight and side-effect results. DOI: 10.1016/S0140-6736(25)02155-5.

Nausea was one of the more common side effects in the Phase 2 study. The percentage varied a lot depending on the study group. Fatigue, meaning feeling unusually tired, was also among the most commonly reported side effects.

These percentages describe reports within each study group, not an individual’s chance of a side effect. The groups were relatively small. Differences between groups do not establish which amount is safest. Larger and longer studies are needed to understand less common and longer-term risks.

Sources: [2] Phase 2 weight and side-effect results. DOI: 10.1016/S0140-6736(25)02155-5.

Eloralintide, also called LY3841136, is an experimental drug from Eli Lilly and Company being studied for weight management. It is designed to copy some effects of amylin, a hormone the body naturally releases after eating. Amylin helps signal fullness and can slow how quickly food leaves the stomach.

Eloralintide is still an experimental drug. It has not been approved by the FDA.

Sources: [5] Current drug development information.

Class: selective amylin receptor agonist. In plain English, it activates selected targets that receive amylin signals.

Developer: Eli Lilly and Company. Category: metabolic / weight management / amylin. Research stage: Phase 3 program underway.

In the completed Phase 2 trial, researchers studied injections under the skin once a week for 48 weeks. Subcutaneous is the medical word for an injection under the skin.

Sources: [1] Phase 2 study design and exact schedules. · [5] Current drug development information.

Eloralintide works through the amylin system. Amylin is a hormone your body naturally releases when you eat. One of its jobs is helping the brain recognize that you have eaten enough. Researchers are studying whether increasing this signal can help people feel full sooner and eat less.

A receptor is a target on a cell that receives a signal. An agonist activates that target. “Selective” describes which targets a drug activates most strongly; it does not mean the drug is free of side effects.

Sources: [3] Mechanism, early human study, and half-life.

Eloralintide is not another version of semaglutide or tirzepatide. GLP-1, short for glucagon-like peptide-1, is another hormone signal involved in hunger and blood sugar. Semaglutide activates that signal. Tirzepatide also activates GIP, short for glucose-dependent insulinotropic polypeptide, another hormone involved in blood sugar control.

Retatrutide is being studied through GLP-1, GIP, and glucagon signals. Eloralintide mainly targets the amylin system. These compounds can affect hunger and fullness through different signals.

Their milligram amounts are not interchangeable. There is no established conversion from Eloralintide to semaglutide, tirzepatide, or retatrutide. This comparison explains mechanisms; it is not advice to combine or switch compounds.

Mechanism guides: Retatrutide · Tirzepatide · Semaglutide.

Sources: [3] Mechanism, early human study, and half-life.

Phase 1 studies are early human studies that help researchers understand how a drug behaves in the body and what side effects occur. One early Eloralintide study included 48 healthy participants and tested single injections.

At four weeks, the groups given a single 4 mg or 12 mg injection had average weight changes of about −2.5% and −4.4%, compared with +0.6% for placebo, an injection without the active drug. These small, short study groups cannot establish long-term safety or predict an individual result.

A separate Phase 1 proof-of-concept publication examined repeated weekly treatment. These early studies help explain why larger trials followed; they do not establish an approved dose.

Sources: [3] Mechanism, early human study, and half-life. · [4] Repeated-dose Phase 1 research. DOI: 10.1111/dom.70439.

Pharmacokinetics means how a drug moves through and leaves the body. About 13–15 days (310–366 hours; 12.9–15.3 days) across single 0.4–12 mg doses in an early human study. Half-life means roughly how long it takes for the amount in the body to drop by half. This does not establish how often someone should take it.

Sources: [3] Mechanism, early human study, and half-life.

The Phase 3 program is underway. Phase 3 studies test a drug in larger groups to learn more about its effects and safety. ENLIGHTEN-1 (NCT07321886) studies adults with obesity or overweight without type 2 diabetes. ENLIGHTEN-2 (NCT07282600) studies adults with obesity or overweight and type 2 diabetes.

A Phase 3 trial is not an approval. The schedules on this page describe the completed Phase 2 trial, not every ENLIGHTEN study.

Sources: [5] Current drug development information. · [6] Phase 3 study without type 2 diabetes. · [7] Phase 3 study with type 2 diabetes.

Eloralintide is investigational, meaning it is still being studied. It is not FDA approved, and there is no approved consumer dosing schedule.

Sources: [5] Current drug development information.

The linked guide explains the weekly amounts and exact week ranges studied in Phase 2. The library presents them as study references, with no recommended or default study arm.

View Phase 2 dosing research · Read the Eloralintide peptide guide · Browse the Peptide Library